Vortioxetine improves cognition in mild cognitive impairment

Area of Science:

• Neuroscience
• Pharmacology
• Gerontology

Background:

• Mild cognitive impairment (MCI) is a growing concern in aging populations.
• Currently, limited pharmacologic interventions exist for MCI.
• Effective treatments are needed to slow cognitive decline and improve quality of life.

Purpose of the Study:

• To investigate the efficacy of vortioxetine in enhancing cognitive function in adults with MCI.
• To assess the impact of vortioxetine on disease severity and safety.
• To explore vortioxetine as a potential treatment for non-depressed individuals with MCI.

Main Methods:

• A single-arm, open-label, phase II study.
• 111 adults with MCI (without depression) received 5-10 mg/day vortioxetine for 6 months.
• Cognitive function was assessed using the Montreal Cognitive Assessment (MoCA) and Digit Symbol Substitution Test (DSST).
• Disease severity was measured by the Clinical Dementia Rating (CDR).

Main Results:

• Mean MoCA scores improved significantly from 24.2 to 29.7, with most participants reaching normal cognitive ranges.
• Both MoCA and DSST scores showed significant improvements at 1, 3, and 6 months (P < 0.001).
• Global CDR scores improved significantly, indicating a shift from very mild impairment to normal status, particularly in memory.
• 89.6% of subjects showed improved disease severity by month 6.
• Vortioxetine demonstrated a favorable safety profile with low incidence of adverse events.

Conclusions:

• Vortioxetine treatment led to significant improvements in cognitive function and disease severity in adults with MCI.
• The drug was well-tolerated, with a low rate of adverse events.
• These findings are encouraging for the development of pharmacologic treatments for MCI and warrant further investigation.